Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus: Tanzania Broadens Choice for COVID - 19 Vaccines The government has so far approved five vaccines to be used in the country, which have also been endorsed by WHO as Pfizer, Johnson & Johnson, Moderna, Sinopharm and Sinovac

11/25/2021 | 01:48am EST

Tanzania on Tuesday received 499,590 doses of Pfizer-Biotech vaccine from the United States under COVAX Facility, a move that provides multiple options for Tanzanians on the types of vaccines they should go for. Pfizer is a third COVID-19 vaccine that has been received in the country; others are Johnson & Johnson from the US and Sinopharm from China.

The government has so far approved five vaccines to be used in the country, which have also been endorsed by WHO as Pfizer, Johnson & Johnson, Moderna, Sinopharm and Sinovac. Under the COVAX arrangement, Tanzania, like other countries will receive vaccines which will cover 20 percent of its total population. Speaking shortly during an event to receive the vaccines, Minister for Health, Community Development, Gender, Elderly and Children, Dr. Dorothy Gwajima assured Tanzanians that the vaccines are safe and have been approved by the World Health Organization (WHO).

"Right now, Tanzanians have multiple options on what kind of vaccine they want to take, they are not limited to one vaccine," she said, commending the US for its continued support for Tanzania. She said, by November 19 this year a total of 1,359,624 Tanzanians were fully vaccinated among whom, 988,293 were injected with a single shot of J & J vaccine while the remaining had received double shots of Sinoparm.

According to her, some 371,331 others received a single shot of Sinopharm. Dr. Gwajima also named Dar es Salaam, Kilimanjaro, Dodoma, Arusha, Mwanza, Ruvuma, Mbeya, Morogoro, Mtwara and Kagera as the best regions that have performed well in the issuance of COVID-19 vaccine. So far, the government has already received a total of 1,227,400 doses of J & J vaccines for 1,227,400, 2,578,400 doses of Sinopharm vaccines for 1,289,200 people as it requires two shots per person.

"The just received 499,590 doses of Pfizer are meant for 249,795 people, the government will use the available scientists to confirm efficacy of the vaccines before being introduced for the use," she assured. The Minister went on to urge Tanzanians who are not yet vaccinated, to consider taking the jab since the vaccines are safe and have been approved by the world class-top laboratories of the WHO.

However, she stressed on the need for the public to adhere to all preventive measures, including wearing masks, washing hands with running water and soap routinely and using hand sanitizers. Other measures outlined include avoid congestion and, where necessary, consider social distancing by at least one meter from one person to another and regular physical exercises coupled with measuring temperature. Earlier, the Ambassador of US to Tanzania, Dr. Donald Wright reiterated the commitment of his government to continue supporting developing countries including Tanzania in fighting the COVID-19 pandemic.

Distributed by APO Group on behalf of Embassy of the United Republic of Tanzania Tel Aviv, Israel.

© African Press Organization, source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 2.86% 167.63 Delayed Quote.-4.73%
MODERNA, INC. -3.03% 152.54 Delayed Quote.-38.07%
All news about JOHNSON & JOHNSON
04:24pNvidia, General Electric fall; IBM, American Express rise
03:49pHealth Care Stocks Still Trying to Overcome Midday Slide
02:14pUS Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers
01:05pHealth Care Stocks Resisting Steeper Tuesday Market Losses
11:44aGLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
11:05aPrescription drugs, medical devices boost J&J in Q4
10:09aWALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
10:02aJohnson & Johnson Posts Higher Fourth-Quarter Earnings; Sees COVID-19 Vaccine Sales of ..
10:01aJohnson & Johnson Forecasts COVID-19 Vaccine Sales Of Up To $3.5 Billion In 2022
09:06aHealth Care Stocks Flat to Lower During Pre-Bell Tuesday
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 304 M - -
Net income 2021 22 542 M - -
Net cash 2021 815 M - -
P/E ratio 2021 19,3x
Yield 2021 2,55%
Capitalization 441 B 441 B -
EV / Sales 2021 4,67x
EV / Sales 2022 4,41x
Nbr of Employees 134 500
Free-Float -
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 162,97 $
Average target price 182,83 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
NOVO NORDISK A/S-17.16%210 749